The EU invests extensively in research to improve the health of Europeans. By focusing on human development and ageing, this research responds to the call for a socially-inclusive Europe.
EU funding in 2011
€ 850.58 million
It also boosts European health-related industries and businesses' competitiveness and innovative capacity. In 2011, EU funding supported SME-intensive research, lifestyle-related and global health issues, immunisation strategies and innovative clinical trials.
In sub-Saharan Africa, the European and Developing Countries Clinical Trials Partnership (EDCTP) accelerated the fight against HIV/AIDS, malaria and tuberculosis. The EDCTP has become a model for joint programming at an international level and its studies have led to new World Health Organisation guidelines. In line with the FP7 Health theme, a successor to EDCTP is currently being considered as part of Horizon 2020.
The Innovative Medicines Initiative Joint Undertaking (IMI JU) aims to optimise patient treatment and therapy by improving the effectiveness of innovative medicines. Thanks to the variety of stakeholders involved in this public-private partnership (from industry, academia, SMEs, regulatory authorities, healthcare providers and patients' organisations), the 23 supported projects are achieving remarkable results in fields such as diabetes and mental health research.
By pooling national research efforts in Joint Programming Initiatives (JPIs) major societal challenges are being addressed more effectively. Already, strategic research agendas have been adopted in the area of neurodegenerative diseases, in particular Alzheimer's.
The FP7 Health theme contributed to developing the pilot European Innovation Partnership (EIP) on Active and Healthy Ageing. This addresses ageing to ensure more years of healthy living for EU citizens.